The 20 Best Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency Doctors Near Me in Ann Arbor, MI

David Bradley is a Pediatrics specialist and a Pediatric Cardiologist in Ann Arbor, Michigan. Dr. Bradley is rated as an Advanced provider by MediFind in the treatment of Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency. His top areas of expertise are Transposition of the Great Arteries, Tetralogy of Fallot, Congenital Heart Block, and Hypoplastic Left Heart Syndrome (HLHS).

David Olson earned his M.D. and Ph.D. at the University of Michigan (the latter in Cellular and Molecular Biology). He served his internship and residency at Children’s Hospital Boston, followed by a fellowship in pediatric endocrinology and metabolism at Children’s Hospital Boston/Joslin Diabetes Center. Prior to returning to the University of Michigan, Dr. Olson was on staff at Children's Hospital Boston and affiliated with the Department of Newborn Medicine at Brigham and Women’s Hospital. His postdoctoral research was performed at Beth Israel Deaconess Medical Center, Division of Endocrinology. Using novel mouse models, Dr. Olson is exploring gene expression changes in specific neuronal populations in the brain that are known to be important in regulating energy balance; these studies are directed at examining the link between gene expression in specific areas of the brain and altered metabolism. Additional studies using neuron-specific genetic changes are underway to clarify the molecular basis of daily biologic rhythms and explore how disruption of these rhythms predisposes organisms (rodents and humans) to pathologic changes in metabolism. Dr. Olson is rated as an Experienced provider by MediFind in the treatment of Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency. His top areas of expertise are Type 1 Diabetes (T1D), Short Stature (Growth Disorders), Idiopathic Short Stature (ISS), and Familial Short Stature (FSS).

Ayesha Ahmad is a Medical Genetics specialist and a Pediatrics provider in Ann Arbor, Michigan. Dr. Ahmad is rated as an Advanced provider by MediFind in the treatment of Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency. Her top areas of expertise are Pompe Disease, Propionic Acidemia, Von Gierke Disease, and Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome).

Tomoyasu Higashimoto is a Medical Genetics specialist and an Internal Medicine provider in Ann Arbor, Michigan. Dr. Higashimoto is rated as an Advanced provider by MediFind in the treatment of Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency. His top areas of expertise are Nevoid Basal Cell Carcinoma Syndrome, Methylmalonic Acidemia, Very Long-Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, and Propionic Acidemia.

Dr. Lee earned her M.D. from Ross University School of Medicine in 2013, and completed Pediatric Residency at Ascension St. John Hospital in Grosse Point, MI, where she served as a Chief Pediatric Resident during her final year of residency. She completed Categorical Medical Genetics Residency at the University of Michigan in 2019. Following this she accepted a dual faculty position as a Clinical Lecturer in the Department of Pediatrics and Department of Internal Medicine for one year, before returning to Fellowship in 2020 to complete additional dedicated training in Medical Biochemical Genetics. After completion of Medical Biochemical Genetics Fellowship, she resumed her faculty position as a Clinical Assistant Professor in 2021. She is board certified in Pediatrics, and in Clinical and General Genetics.She has a dual faculty appointment in the Department of Pediatrics and the Department of Internal Medicine. As a faculty member in the Department of Pediatrics, she sees patients in the Pediatric Genetics and Biochemical Genetics Clinics, in addition to the newly created Multidisciplinary Genetics of Hearing Loss Clinic. As a faculty member in the Department of Internal Medicine, she sees patients in the Adult Medical Genetics and Cancer Genetics Clinics, in addition to patients with atypical diabetes and/or lipodystrophy in collaboration with MEND.In addition to her clinical responsibilities, Dr. Lee also enjoys spending time teaching and discussing various aspects of genetics with fellows, pediatric residents, medical students, and genetic counseling students. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency. Her top areas of expertise are Biotinidase Deficiency, Delayed Growth, Beta-Ketothiolase Deficiency, and Triple X Syndrome.

Dr. Pritchard is a Michigan native who returned to the University of Michigan to join the faculty here in 2019 after completing her pediatrics and genetics residencies and biochemical genetics fellowship. She enjoys care of complex patients with rare genetic diseases. Dr. Pritchard is active in medical education as Program Director for the Medical Biochemical Genetics Fellowship program and Associate Program Director for the Medical Genetics and Genomics training programs.Outside of work, Dr. Pritchard enjoys cooking, reading, hiking, and spending time with her husband and two daughters. Dr. Pritchard is rated as an Experienced provider by MediFind in the treatment of Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency. Her top areas of expertise are Microcephaly Deafness Syndrome, Propionic Acidemia, Delayed Growth, and Cohen Syndrome.

Dr. Feldman is the director of the NeuroNetwork for Emerging Therapies at Michigan Medicine and the ALS Center of Excellence at Michigan Medicine. The latter includes the Pranger ALS Clinic, one of the top multidisciplinary clinics caring for those suffering from amyotrophic lateral sclerosis (ALS). She serves as the University of Michigan James W. Albers Distinguished University Professor and the Russell N. DeJong Professor of Neurology at Michigan Medicine. Dr. Feldman is one of the world’s leading authorities on neurodegenerative disease.Dr. Feldman is a compassionate and dedicated physician who cares deeply about her patients. She has been recognized for her clinical excellence by numerous organizations and is annually named as one of the “Best Doctors in America.” Her forward-thinking, collaborative, multidisciplinary approach has transformed how neurodegenerative diseases are diagnosed, treated, and prevented.Dr. Feldman has made significant contributions to biomedical research and clinical care in many critical areas of neurodegenerative disease. She has authored over 530 peer-reviewed publications, 74 book chapters, and 5 books on the pathology, diagnosis, and treatment of neurological diseases. Dr. Feldman has been continuously funded by the NIH since 1989 and is currently the principal or co-investigator of numerous clinical trials and grants. She has received numerous awards and honors throughout her remarkable career, including the University of Michigan’s Early Distinguished Career Award, the Distinguished Faculty Achievement Award, and the Distinguished Alumnus Achievement Award. She was also the first woman in 25 years to receive the Robert S. Schwab Award from the American Clinical Neurophysiology Society. In 2022, Dr. Feldman was awarded the University of Michigan Distinguished Professorship, the highest faculty honor at University of Michigan.Dr. Feldman is actively committed to and involved in professional service. She served as President of the Peripheral Nerve Society from 2007-2009 and President of the American Neurological Association (ANA) from 2011-2013. Dr. Feldman is an elected member of the National Academy of Medicine (NAM) and Association of American Physicians, and a Fellow of the American Association for the Advancement of Science. Dr. Feldman is the Editor of the Contemporary Neurology Series and also serves on a number of editorial boards for leading scientific journals, including The Lancet Neurology, Nature Reviews Neurology, JAMA Neurology and Journal of Neurology, Neurosurgery and Psychiatry. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Succinyl-CoA:3-Ketoacid CoA Transferase Deficiency. Her top areas of expertise are Peripheral Neuropathy, Diabetic Neuropathy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Autonomic Neuropathy.